Applicability-domain-aware cheminformatics and structure-based prioritization of HER2 kinase inhibitor analogs.
An applicability-domain-aware workflow for prioritizing scaffold-constrained HER2 kinase inhibitor analogs is developed, providing a reproducible computational route for selecting experimentally testable HER2 analogs while keeping model extrapolation, chemical diversity, and structure-based interpretation explicit.